Clinical Trial Update: CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma [Phase 2]

View source ↗

Summary

CAMPFIRE is a Phase 2 study of Abemaciclib (LY2835219) in participants with Ewing sarcoma. Results were posted on March 12, 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sarcoma, Ewing, Neoplasm Metastasis | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-12